Walleye Capital
PHAT icon

Walleye Capital’s Phathom Pharmaceuticals PHAT Stock Holding History

Walleye Capital’s Portfolio PHAT Stock Details PHAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-290,467
Closed -$3.42M – 4988
2025
Q3 		$3.42M Buy
+290,467
New +$3M 0.01% 1188
2024
Q1 		– Sell
-202,154
Closed -$1.85M – 5775
2023
Q4 		$1.85M Buy
202,154
+116,782
+137% +$1.01M ﹤0.01% 1853
2023
Q3 		$885K Buy
+85,372
New +$1.17M ﹤0.01% 2342
2023
Q1 		– Sell
-145,870
Closed -$1.64M – 4269
2022
Q4 		$1.64M Buy
+145,870
New +$1.5M 0.03% 695
2022
Q3 		– Sell
-83,031
Closed -$701K – 3457
2022
Q2 		$701K Buy
+83,031
New +$854K 0.02% 826

Other funds holding PHAT

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Walleye Capital's PHAT Position: Q4 2025 in Review

Walleye Capital sold out of Phathom Pharmaceuticals (PHAT) in Q4 2025, closing a stake of 290,467 shares — an estimated $3.42M sold.

Walleye Capital first reported a position in PHAT in Q2 2022 and held it in 5 quarters. The position peaked at $3.42M in Q3 2025. 172 funds tracked by Wall St. Rank hold PHAT as of Q4 2025.

  • Walleye Capital reported no remaining Phathom Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Walleye Capital sold 290,467 Phathom Pharmaceuticals shares in Q4 2025, an estimated $3.42M.
  • Walleye Capital first reported a position in Phathom Pharmaceuticals in Q2 2022 and held it in 5 quarters.
  • Walleye Capital's Phathom Pharmaceuticals position peaked at $3.42M in Q3 2025.
  • 172 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q4 2025.

Based on Walleye Capital's 13F filing for Q4 2025, filed 13 Feb 2026.